WJCD  Vol.4 No.12 , November 2014
Elderly Disabled Patients in Oral Anticoagulation Treatment: An Evaluation of a Bioanalyst-Led Management Program Reaching an Average of 72% of Time in Therapeutic Range
Introduction: The need for anticoagulation therapy increases with age, mainly due to the increased prevalence of atrial fibrillation. Time in therapeutic range (TTR) is a marker of the quality of the therapy as TTR is inversely correlated with adverse reactions. We developed a bioanalyst-led management program for control of warfarin treatment in elderly disabled patients in their own home and maintain a high TTR. Material and Methods: Residents in nursing home settings were included. Visiting nurses measured INR with a point of care testing device. If INR was within Therapeutic Range (TR), the nurse dosed warfarin unaltered. If INR was out of TR, the visiting nurse contacted a specially trained bioanalyst by phone. An explanation was sought, and a new dosage plan was made. Results: A total of 579 patients were included; 356 females (61%). Mean age was 79.6 years. Approximately 10% were residents in nursing home settings and the rest in domiciliary care. TTR was 72%. The subtherapeutic values were 15% and supratherapeutic values 13%. In total, 139 patients died during the study period. Ten deaths could be related to possible side effects of warfarin treatment. Conclusions: Our results indicate that a bioanalyst-led program is able to simplify anticoagulation monitoring, while maintaining INR control similar to a specialized clinic. Furthermore, we avoided hospitalizations when INR was unacceptably high by treating the patient with oral vitamin-K at home. Our findings could be helpful when planning warfarin treatment in elderly, fragile patients.

Cite this paper
Vedtofte, T. , Melsen, G. , Bathum, L. , Ellervik, C. and Jørgensen, M. (2014) Elderly Disabled Patients in Oral Anticoagulation Treatment: An Evaluation of a Bioanalyst-Led Management Program Reaching an Average of 72% of Time in Therapeutic Range. World Journal of Cardiovascular Diseases, 4, 623-630. doi: 10.4236/wjcd.2014.412074.
[1]   Christensen, K., Doblhammer, G., Rau, R. and Vaupel, J.W. (2009) Ageing Populations: The Challenges Ahead. Lancet, 374, 1196-1208.

[2]   Field, T.S., Tjia, J., Mazor, K.M., Donovan, J.L., Kanaan, A.O., Harrold, L.R., Reed, G., Doherty, P., Spenard, A. and Gurwitz, J.H. (2011) Randomized Trial of a Warfarin Communication Protocol for Nursing Homes: An SBAR-Based Approach. The American Journal of Medicine, 124, 179.e1-179.e7.

[3]   Wolf, P.A., Abbott, R.D. and Kannel, W.B. (1991) Atrial Fibrillation as an Independent Risk Factor for Stroke: The Framingham Study. Stroke, 22, 983-988.

[4]   Whitlock, R.P., Sun, J.C., Fremes, S.E., Rubens, F.D. and Teoh, K.H. (2012) Antithrombotic and Thrombolytic Therapy for Valvular Disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th Edition: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 141, e576S-e600S.

[5]   Bauersachs, R.M. (2012) Use of Anticoagulants in Elderly Patients. Thrombosis Research, 129, 107-115.

[6]   Schmitt, L., Speckman, J. and Ansell, J. (2003) Quality Assessment of Anticoagulation Dose Management: Comparative Evaluation of Measures of Time-in-Therapeutic Range. Journal of Thrombosis and Thrombolysis, 15, 213-216.

[7]   Morgan, C.L., McEwan, P., Tukiendorf, A., Robinson, P.A., Clemens, A. and Plumb, J.M. (2009) Warfarin Treatment in Patients with Atrial Fibrillation: Observing Outcomes Associated with Varying Levels of INR Control. Thrombosis Research, 124, 37-41.

[8]   Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W. and Radford, M.J. (2001) Validation of Clinical Classification Schemes for Predicting Stroke: Results from the National Registry of Atrial Fibrillation. JAMA, 285, 2864-2870.

[9]   van den Ham, H.A., Klungel, O.H., Leufkens, H.G. and van Staa, T.P. (2012) The Patterns of Anticoagulation Control and the Risk of Stroke, Bleeding and Mortality in Patients with Non-Valvular Atrial Fibrillation. Journal of Thrombosis and Haemostasis, 11, 107-115.

[10]   Gallagher, A.M., Setakis, E., Plumb, J.M., Clemens, A. and van Staa, T.P. (2011) Risks of Stroke and Mortality Associated with Suboptimal Anticoagulation in Atrial Fibrillation Patients. Thromb Haemost, 106, 968-977.

[11]   Verhovsek, M., Motlagh, B., Crowther, M.A., Kennedy, C., Dolovich, L., Campbell, G., Wang, L. and Papaioannou, A. (2008) Quality of Anticoagulation and Use of Warfarin-Interacting Medications in Long-Term Care: A Chart Review. BMC Geriatrics, 3, 8-13.

[12]   Fang, M.C., Chang, Y., Hylek, E.M., Rosand, J., Greenberg, S.M., Go, A.S. and Singer, D.E. (2004) Advanced Age, Anticoagulation Intensity, and Risk for Intracranial Hemorrhage among Patients Taking Warfarin for Atrial Fibrillation. Annals of Internal Medicine, 141, 745-752.

[13]   Chitsike, R.S., Rodger, M.A., Kovacs, M.J., Betancourt, M.T., Wells, P.S., Anderson, D.R., Chagnon, I., Le Gal, G., Solymoss, S., Crowther, M.A., Perrier, A., White, R.H., Vickars, L.M., Ramsay, T. and Kahn, S.R. (2012) Risk of Post-Thrombotic Syndrome after Subtherapeutic Warfarin Anticoagulation for a First Unprovoked Deep Vein Thrombosis: Results from the REVERSE Study. Journal of Thrombosis and Haemostasis, 10, 2039-2044.

[14]   Andersson, M.L., Lindh, J.D. and Mannheimer, B. (2013) The Impact of Interacting Drugs on Dispensed Doses of Warfarin in the Swedish Population: A Novel Use of Population Based Drug Registers. The Journal of Clinical Pharmacology, 53, 1322-1327.

[15]   Greenblatt, D.J. and Von Moltke, L.L. (2005) Interaction of Warfarin with Drugs, Natural Substances, and Foods. The Journal of Clinical Pharmacology, 45, 127-132.

[16]   Demirkan, K., Stephens, M.A., Newman, K.P. and Self, T.H. (2000) Response to Warfarin and Other Oral Anticoagulants: Effects of Disease States. Southern Medical Journal, 93, 448-454.

[17]   Gage, B.F., Fihn, S.D. and White, R.H. (2000) Management and Dosing of Warfarin Therapy. The American Journal of Medicine, 109, 481-488.

[18]   Rosendaal, F.R., Cannegieter, S.C., Van der Meer, F.J. and Briet, E. (1993) A Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy. Thrombosis and Haemostasis, 69, 236-239.

[19]   Aspinall, S.L., Zhao, X.H., Handler, S.M., Stone, R.A., Kosmoski, J.C., Libby, E.A., Francis, S.D., Goodman, D.A., Roman, R.D., Bieber, H.L., Voisine, J.M., Jeffery, S.M., Hepfinger, C.A., Hagen, D.G., Martin, M.M. and Hanlon, J.T. (2010) The Quality of Warfarin Prescribing and Monitoring in Veterans Affairs Nursing Homes. Journal of the American Geriatrics Society, 58, 1475-1480.

[20]   Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., Lewis, B.S., Darius, H., Diener, H.C., Joyner, C.D. and Wallentin, L. (2009) Dabigatran versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 361, 1139-1151.

[21]   Granger, C.B., Alexander, J.H., McMurray, J.J., Lopes, R.D., Hylek, E.M., Hanna, M., Al-Khalidi, H.R., Ansell, J., Atar, D., Avezum, A., Bahit, M.C., Diaz, R., Easton, J.D., Ezekowitz, J.A., Flaker, G., Garcia, D., Geraldes, M., Gersh, B.J., Golitsyn, S., Goto, S., Hermosillo, A.G., Hohnloser, S.H., Horowitz, J., Mohan, P., Jansky, P., Lewis, B.S., Lopez-Sendon, J.L., Pais, P., Parkhomenko, A., Verheugt, F.W., Zhu, J. and Wallentin, L. (2011) Apixaban versus Warfarin in Patients with Atrial Fibrillation. New England Journal of Medicine, 365, 981-992.

[22]   Gurwitz, J.H., Field, T.S., Radford, M.J., Harrold, L.R., Becker, R., Reed, G., DeBellis, K., Moldoff, J. and Verzier, N. (2007) The Safety of Warfarin Therapy in the Nursing Home Setting. The American Journal of Medicine, 120, 539-544.

[23]   Han, S.Y., Palmeri, S.T., Broderick, S.H., Hasselblad, V., Rendall, D., Stevens, S., Tenaglia, A., Velazquez, E., Whellan, D., Wagner, G. and Heitner, J.F. (2013) Quality of Anticoagulation with Warfarin in Patients with Nonvalvular Atrial Fibrillation in the Community Setting. Journal of Electrocardiology, 46, 45-50.

[24]   Hassan, S., Naboush, A., Radbel, J., Asaad, R., Alkaied, H., Demissie, S. and Terjanian, T. (2013) Telephone-Based Anticoagulation Management in the Homebound Setting: A Retrospective Observational Study. International Journal of General Medicine, 6, 869-875.

[25]   McCormick, D., Gurwitz, J.H., Goldberg, R.J., Becker, R., Tate, J.P., Elwell, A. and Radford, M.J. (2001) Prevalence and Quality of Warfarin Use for Patients with Atrial Fibrillation in the Long-Term Care Setting. Archives of Internal Medicine, 161, 2458-2463.

[26]   Melamed, O.C., Horowitz, G., Elhayany, A. and Vinker, S. (2011) Quality of Anticoagulation Control among Patients with Atrial Fibrillation. The American Journal of Managed Care, 17, 232-237.

[27]   Nelson, W.W., Choi, J.C., Vanderpoel, J., Damaraju, C.V., Wildgoose, P., Fields, L.E. and Schein, J.R. (2013) Impact of Co-Morbidities and Patient Characteristics on International Normalized Ratio Control over Time in Patients with Nonvalvular Atrial Fibrillation. American Journal of Cardiology, 112, 509-512.

[28]   Papaioannou, A., Kennedy, C.C., Campbell, G., Stroud, J.B., Wang, L.Q., Dolovich, L. and Crowther, M.A. (2010) A Team-Based Approach to Warfarin Management in Long Term Care: A Feasibility Study of the MEDeINR Electronic Decision Support System. BMC Geriatrics, 10, 10-38.

[29]   Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Halperin, J.L., Hankey, G.J., Piccini, J.P., Becker, R.C., Nessel, C.C., Paolini, J.F., Berkowitz, S.D., Fox, K.A. and Califf, R.M. (2011) Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation. New England Journal of Medicine, 365, 883-891.

[30]   Plichart, M., Berrut, G., Maubourguet, N., Jeandel, C., Emeriau, J.P., Ankri, J., Bouvier, H., Ruault, G. and Hanon, O. (2013) Use of Vitamin K Antagonist Therapy in Geriatrics: A French National Survey from the French Society of Geriatrics and Gerontology (SFGG). Drugs & Aging, 30, 1019-1028.

[31]   Wieloch, M., Sjalander, A., Frykman, V., Rosenqvist, M., Eriksson, N. and Svensson, P.J. (2011) Anticoagulation Control in Sweden: Reports of Time in Therapeutic Range, Major Bleeding, and Thrombo-Embolic Complications from the National Quality Registry AuriculA. European Heart Journal, 32, 2282-2289.

[32]   Rossiter, J., Soor, G., Telner, D., Aliarzadeh, B. and Lake, J. (2013) A Pharmacist-Led Point-of-Care INR Clinic: Optimizing Care in a Family Health Team Setting. International Journal of Family Medicine, 2013, Article ID: 691454.

[33]   Gupta, V., Kogut, S.J. and Thompson, S. (2013) Evaluation of Differences in Percentage of International Normalized Ratios in Range between Pharmacist-Led and Physician-Led Anticoagulation Management Services. Journal of Pharmacy Practice, 45, 127-132.

[34]   Ansell, J., Hirsh, J., Hylek, E., Jacobson, A., Crowther, M. and Palareti, G. (2008) Pharmacology and Management of the Vitamin K Antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 133, 160S-198S.

[35]   Maher, R.L., Hanlon, J. and Hajjar, E.R. (2014) Clinical Consequences of Polypharmacy in Elderly. Expert Opinion on Drug Safety, 13, 57-65.

[36]   Meegaard, P.M., Holck, L.H., Pottegard, A., Madsen, H. and Hallas, J. (2012) Excessive Anticoagulation with Warfarin or Phenprocoumon May Have Multiple Causes. Danish Medical Journal, 59, A4383.

[37]   Torn, M., Bollen, W.L., Van der Meer, F.J., Van der Wall, E.E. and Rosendaal, F.R. (2005) Risks of Oral Anticoagulant Therapy with Increasing Age. Archives of Internal Medicine, 165, 1527-1532.

[38]   Witt, D.M., Delate, T., Hylek, E.M., Clark, N.P., Crowther, M.A., Dentali, F., Ageno, W., Martinez, K.D. and Garcia, D.A. (2013) Effect of Warfarin on Intracranial Hemorrhage Incidence and Fatal Outcomes. Thrombosis Research, 132, 770-775.

[39]   Casciano, J.P., Dotiwala, Z.J., Martin, B.C. and Kwong, W.J. (2013) The Costs of Warfarin Underuse and Nonadherence in Patients with Atrial Fibrillation: A Commercial Insurer Perspective. Journal of Managed Care Pharmacy, 19, 302-316.

[40]   Zimetbaum, P.J., Thosani, A., Yu, H.T., Xiong, Y., Lin, J., Kothawala, P. and Emons, M. (2010) Are Atrial Fibrillation Patients Receiving Warfarin in Accordance with Stroke Risk? The American Journal of Medicine, 123, 446-453.

[41]   Pugh, D., Pugh, J. and Mead, G.E. (2011) Attitudes of Physicians Regarding Anticoagulation for Atrial Fibrillation: A Systematic Review. Age and Ageing, 40, 675-683.

[42]   Crowther, M.A., Donovan, D., Harrison, L., McGinnis, J. and Ginsberg, J. (1998) Low-Dose Oral Vitamin K Reliably Reverses Over-Anticoagulation Due to Warfarin. Thrombosis and Haemostasis, 79, 1116-1118.